At ImmunoBio, we’re motivated by a strong commitment to improving health and prolonging life. We’re particularly passionate about combating the world’s most serious diseases using our breakthrough vaccine platform, ICV. This proprietary technology safely combines specific viruses with corresponding antibodies to create novel vaccines with significantly improved performance.

Currently we’re exploring vaccine possibilities on several fronts: our animal models show good proof-of-concept data for human Respiratory Syncytial virus (hRSV) and promising trend analysis for Adenovirus vector in gene delivery. In addition, we have an ongoing, joint exploration of a vaccine using dengue fever virus and are optimistic about our research into a cross-strain human influenza vaccine.

We’re excited and hopeful about ICV’s potential to improve life-changing vaccines. Conceptually simple, creating vaccines by combining antigens and antibodies nonetheless offers multiple benefits, including production consistency, increased safety, reduced toxicity, and improved efficacy.

If you’re on the lookout for innovations that offer great hope for improved vaccines, you’ve found your partner in ImmunoBio Sciences.

Better health through better vaccines